WES for clinical anaplastic thyroid carcinoma revealed that mTOR mutations conferred resistance to mTOR inhibition,39 while certain mTOR mutations prevented binding of the FKBP12–rapamycin complex to mTORC1.8 This evidence concerns the gene FKBP1A and thyroid gland undifferentiated (anaplastic) carcinoma.